An Academic Resource for Peptide Therapeutics Research
BioTech Pharma is an independent, non-clinical academic resource that synthesizes peer-reviewed literature on bioactive peptides. The Institute does not manufacture, distribute, or recommend the use of any compound. Its remit is strictly informational: to support researchers, graduate students, and clinical investigators with rigorously curated literature reviews, mechanism-of-action summaries, and references to primary sources.
Research Mission
The Institute exists to bridge a persistent gap in peptide therapeutics research: the absence of a single, well-curated point of entry into the rapidly expanding primary literature. While individual peptides are extensively studied across thousands of publications in fields ranging from gastroenterology to neuroendocrinology, the dispersion of evidence across journals, time periods, and research traditions can make systematic review preparation, grant writing, and protocol development unnecessarily time-consuming. BioTech Pharma aggregates, screens, and synthesizes this literature into structured profiles that researchers can use as the foundation for deeper investigation.
Each entry in the database is constructed to mirror the analytical frame of a contemporary scholarly review article: clear molecular characterization, transparent description of mechanisms of action and the strength of evidence supporting each, structured presentation of preclinical and clinical findings, explicit discussion of methodological limitations, and a comprehensive reference list. We have deliberately avoided the format of a textbook or a clinical reference; the Institute's audience consists of practicing researchers, and the literature reviews are written for that audience.
Editorial Standards
Content development follows protocols aligned with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) framework where applicable, with modifications appropriate to the narrative review format. Each peptide profile undergoes a multi-stage process: (1) systematic database searches across PubMed, Web of Science, and Scopus; (2) screening of identified records for relevance and methodological soundness; (3) data extraction using standardized templates capturing molecular properties, mechanisms, preclinical and clinical evidence, safety data, and regulatory status; (4) critical appraisal of study quality, with reference to validated instruments such as the Cochrane Risk of Bias tool and SYRCLE's risk of bias tool for animal studies; and (5) peer verification by independent reviewers prior to publication.
The Institute maintains an explicit policy of including both positive and negative findings, and of distinguishing clearly between preclinical signals, early-phase clinical data, and high-quality randomized trial evidence. Where the literature is limited, contradictory, or methodologically constrained, the reviews say so. This stance reflects the conviction that the long-term utility of a literature resource depends on its honesty about the strength of the evidence it summarizes.
Curation Methodology
Inclusion criteria for primary references prioritize: peer-reviewed publications in indexed journals; mechanistic studies that contribute substantively to understanding of structure-activity relationships, receptor pharmacology, or downstream signaling; preclinical studies with explicit attention to randomization, blinding, and sample size justification; and human clinical trials with clearly described designs and outcome measures. Case reports and case series are included where they contribute unique observations or represent the only available human data for an indication, with explicit annotation of their limitations.
Citation density across the database averages 3-5 references per 1,000 words of analytical text, with primary references linked directly to PubMed records, DOIs, or other persistent identifiers wherever available. Reference lists are presented in numbered bibliography style consistent with biomedical publication conventions, and intra-document citation anchors permit direct navigation between in-text citations and the corresponding reference entries.
Editorial Board and Contributors
The Institute's editorial work is led by Dr. Sarah Whitfield, PhD (Pharmacology), whose academic background includes graduate training in molecular pharmacology and postdoctoral work in receptor pharmacology and peptide therapeutics. Dr. Whitfield's editorial approach emphasizes mechanistic depth, methodological rigor, and clarity of presentation appropriate for a scholarly audience. Contributing reviewers include researchers active in pharmacology, endocrinology, neuroscience, and translational medicine; contributor identities are aggregated at the Institute level rather than attributed to individual articles, reflecting our model of collaborative editorial review.
The Institute does not accept industry sponsorship for individual content development, does not display advertising, and does not endorse specific commercial products or suppliers. All editorial decisions regarding inclusion, scope, and presentation rest with the editorial board. Researchers wishing to suggest topics for inclusion, contribute as reviewers, or flag corrections may reach the editorial team via the contact page.
Database Scope
The current database comprises systematic literature reviews of 27 therapeutically relevant peptides spanning multiple categories: growth hormone secretagogues (Ipamorelin, Hexarelin, GHRP-2, GHRP-6), GHRH analogs (Sermorelin, CJC-1295, Tesamorelin), tissue repair peptides (BPC-157, TB-500, GHK-Cu, MGF), neuropeptides and nootropics (Cerebrolysin, Semax, Selank, DSIP), immunomodulatory peptides (Thymosin Alpha-1, Thymalin, KPV, LL-37), reproductive endocrinology (Kisspeptin, Triptorelin), melanocortin agonists (Melanotan-2, PT-141), mitochondrial peptides (MOTS-c), longevity/telomere research (Epithalon), regenerative peptides (Thymosin Beta-4), and peptide hormones (Vasopressin).
The scope is deliberately weighted toward compounds with active preclinical and translational research programs, where a synthesizing review can add the most value to working researchers. Coverage is reviewed periodically and expanded as compounds attract sufficient primary literature to support a substantive entry.
Disclaimers and Limitations
The content of this database is intended for academic and research informational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Many compounds reviewed here are investigational and lack regulatory approval for clinical use in human populations. Researchers conducting any laboratory or clinical investigation involving these compounds remain solely responsible for compliance with institutional, regulatory, and ethical requirements governing such research.
The Institute makes no claim that its reviews are exhaustive; researchers should always conduct independent literature searches of primary databases to ensure coverage appropriate to their specific aims. Reviews are updated periodically as the underlying literature evolves, but readers should verify current evidence directly via PubMed or equivalent sources for time-sensitive applications such as grant submissions and protocol design.